董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Glassman | 男 | Chairperson of the Board | 61 | 8.59万美元 | 33.14 | 2026-07-10 |
| Steven A. Ciardiello | 男 | Independent Director | 55 | 4.45万美元 | 12.51 | 2026-07-10 |
| Scott R Henry | 男 | Independent Director | 55 | 8.59万美元 | 未持股 | 2026-07-10 |
| Brian J. Kieser | 男 | Independent Director | 59 | 未披露 | 108.19 | 2026-07-10 |
| Kevin M. Harris | 男 | Independent Director | 51 | 未披露 | 未持股 | 2026-07-10 |
| Jerome B. Zeldis | 男 | Independent Director | 76 | 6.47万美元 | 22.66 | 2026-07-10 |
| Adam Levy | 男 | Chief Executive Officer,Director and President | 63 | 87.72万美元 | 42.25 | 2026-07-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ian Blackman | 男 | Chief Financial Officer | 58 | 未披露 | 6.25 | 2026-07-10 |
| Adam Levy | 男 | Chief Executive Officer,Director and President | 63 | 87.72万美元 | 42.25 | 2026-07-10 |
董事简历
中英对照 | 中文 | 英文- Steven Glassman
-
Steven Glassman自2021年3月8日起担任我们的董事会成员。自2018年1月以来，格拉斯曼先生一直担任Nephila Advisors，LLC的全球业务计划职务，该公司是一家总部位于田纳西州纳什维尔的公司，专注于与资本市场相关的灾难性再保险和天气风险转移市场。从2010年到2017年，Glassman先生担任Nephila Capital Ltd.的首席管理官。Glassman先生拥有范德比尔特大学经济学文学学士学位。
Steven Glassman has served on Nexgel, Inc.'s Board since March 8, 2021 and serves as Chairperson of the Board. He is currently the senior business advisor for Nephila Advisors, LLC, a Nashville, TN based hedge fund focused on catastrophic reinsurance and weather risk transfer markets in connection with the capital markets. From January 2018 to the present, Mr. Glassman has focused on Global Business Initiatives at Nephila. From 2010 to 2017, Mr. Glassman served as the Chief Management Officer of Nephila Capital Ltd. Prior to joining Nephila, Mr. Glassman worked at Merrill Lynch in New York in their real estate principal investment group from 1986 to 2009. Mr. Glassman holds a Bachelor of Arts in Economics from Vanderbilt University. Mr. Glassman has to the Board more than 30 years of business related experience, with expertise in finance, auditing and accounting, which makes him a well qualified candidate to be a director of the Company. - Steven Glassman自2021年3月8日起担任我们的董事会成员。自2018年1月以来，格拉斯曼先生一直担任Nephila Advisors，LLC的全球业务计划职务，该公司是一家总部位于田纳西州纳什维尔的公司，专注于与资本市场相关的灾难性再保险和天气风险转移市场。从2010年到2017年，Glassman先生担任Nephila Capital Ltd.的首席管理官。Glassman先生拥有范德比尔特大学经济学文学学士学位。
- Steven Glassman has served on Nexgel, Inc.'s Board since March 8, 2021 and serves as Chairperson of the Board. He is currently the senior business advisor for Nephila Advisors, LLC, a Nashville, TN based hedge fund focused on catastrophic reinsurance and weather risk transfer markets in connection with the capital markets. From January 2018 to the present, Mr. Glassman has focused on Global Business Initiatives at Nephila. From 2010 to 2017, Mr. Glassman served as the Chief Management Officer of Nephila Capital Ltd. Prior to joining Nephila, Mr. Glassman worked at Merrill Lynch in New York in their real estate principal investment group from 1986 to 2009. Mr. Glassman holds a Bachelor of Arts in Economics from Vanderbilt University. Mr. Glassman has to the Board more than 30 years of business related experience, with expertise in finance, auditing and accounting, which makes him a well qualified candidate to be a director of the Company.
- Steven A. Ciardiello
-
Steven A. Ciardiello，是Shutterstock，Inc的首席会计官，该公司是一家全球领先的创意平台，为变革性品牌、数字媒体和营销公司提供高质量的创意内容，自2016年11月起任职。在担任这一职务期间，他负责监督Shutterstock的内部和外部会计和报告、税务服务以及萨班斯-奥克斯利内部控制职能。在加入Shutterstock之前，Ciardiello先生曾于2015年11月至2016年11月在共享工作空间的领先提供商WeWork Companies，Inc.担任会计主管，于2014年9月至2015年11月在专业财产和意外伤害保险产品的跨国提供商AmTrust Financial Services，Inc.担任财务副总裁，并于2010年7月至2014年9月在财产和意外伤害保险提供商城堡集团担任多项职务，晋升为董事副总裁-首席会计官。Ciardiello先生还曾在Deloitte & Touche LLP和PricewaterhouseCoopers LLP从事公共会计工作15年。Ciardiello先生是一名注册会计师，在伊利诺伊大学获得经济学学士学位。
Steven A. Ciardiello has served on Nexgel, Inc.'s Board since July 31, 2025. Mr. Ciardiello is a Certified Public Accountant who currently serves as the Chief Accounting Officer of Shutterstock, Inc. (NYSE: SSTK), a leading global creative platform offering high quality creative content for transformative brands, where he has served since 2016 and leads a global finance team responsible for SEC reporting, tax, internal audit, and general accounting. Since joining Shutterstock, Mr. Ciardiello has led numerous financial transformation initiatives, improved reporting efficiency, and led efforts to streamline enterprise resource planning and financial operations. Prior to Shutterstock, Mr. Ciardiello held several finance leadership positions, overseeing the redesign of the financial close process and implementation of a global ERP system, and has over 15 years of Big Four public accounting experience. Mr. Ciardiello has to the Board more than 25 years of senior financial leadership experience in publicly traded companies, with expertise in SEC reporting, internal audit, financial transformation and corporate governance, which makes him a well qualified candidate to be a director of the Company. - Steven A. Ciardiello，是Shutterstock，Inc的首席会计官，该公司是一家全球领先的创意平台，为变革性品牌、数字媒体和营销公司提供高质量的创意内容，自2016年11月起任职。在担任这一职务期间，他负责监督Shutterstock的内部和外部会计和报告、税务服务以及萨班斯-奥克斯利内部控制职能。在加入Shutterstock之前，Ciardiello先生曾于2015年11月至2016年11月在共享工作空间的领先提供商WeWork Companies，Inc.担任会计主管，于2014年9月至2015年11月在专业财产和意外伤害保险产品的跨国提供商AmTrust Financial Services，Inc.担任财务副总裁，并于2010年7月至2014年9月在财产和意外伤害保险提供商城堡集团担任多项职务，晋升为董事副总裁-首席会计官。Ciardiello先生还曾在Deloitte & Touche LLP和PricewaterhouseCoopers LLP从事公共会计工作15年。Ciardiello先生是一名注册会计师，在伊利诺伊大学获得经济学学士学位。
- Steven A. Ciardiello has served on Nexgel, Inc.'s Board since July 31, 2025. Mr. Ciardiello is a Certified Public Accountant who currently serves as the Chief Accounting Officer of Shutterstock, Inc. (NYSE: SSTK), a leading global creative platform offering high quality creative content for transformative brands, where he has served since 2016 and leads a global finance team responsible for SEC reporting, tax, internal audit, and general accounting. Since joining Shutterstock, Mr. Ciardiello has led numerous financial transformation initiatives, improved reporting efficiency, and led efforts to streamline enterprise resource planning and financial operations. Prior to Shutterstock, Mr. Ciardiello held several finance leadership positions, overseeing the redesign of the financial close process and implementation of a global ERP system, and has over 15 years of Big Four public accounting experience. Mr. Ciardiello has to the Board more than 25 years of senior financial leadership experience in publicly traded companies, with expertise in SEC reporting, internal audit, financial transformation and corporate governance, which makes him a well qualified candidate to be a director of the Company.
- Scott R Henry
-
Scott R. Henry自2023年1月16日起在NexGel, Inc.的董事会任职。Henry先生，CFA，是Alliance 伙伴全球的董事总经理、高级研究分析师，在制药、生物技术和医疗器械领域拥有25年以上的卖方覆盖经验。此前，他曾在ROTH Capital Partners、Oppenheimer、Thomas Weisel Partners、ABN AMRO和Leerink Swann & Co.等公司任职。Henry先生获得了无数奖项，包括华尔街日报“街头最佳”选股调查排名、福布斯/ZACS Investment Research药物类别“最佳分析师”排名以及Forbes.com/StarMine收益估计准确性排名。他的投资观点被《华尔街日报》和《纽约时报》引用，并在CNBC、CBS MarketWatch和彭博社频繁露面。Henry先生就读于罗德岛大学，并以优异的成绩获得了康奈尔大学的工商管理硕士学位。
Scott R Henry has served on Nexgel, Inc.'s Board since January 16, 2023. Mr. Henry, CFA, is a Managing Director, Senior Research Analyst at Alliance Global Partners with 25+ years of sell side coverage in the pharmaceutical, biotechnology and medical device sectors. He has previously held positions with firms including ROTH Capital Partners, Oppenheimer, Thomas Weisel Partners, ABN AMRO and Leerink Swann & Co. Mr. Henry has received numerous awards, including rankings in the Wall Street Journal "Best on the Street" stock picking survey, Forbes/Zacks Investment Research "Best Analysts" for the drugs category and Forbes.com/StarMine rankings for earnings estimate accuracy. His investment views have been cited in the Wall Street Journal and the New York Times, and he has made frequent appearances on CNBC, CBS MarketWatch and Bloomberg. Mr. Henry attended the University of Rhode Island and received an M.B.A. with distinction from Cornell University. - Scott R. Henry自2023年1月16日起在NexGel, Inc.的董事会任职。Henry先生，CFA，是Alliance 伙伴全球的董事总经理、高级研究分析师，在制药、生物技术和医疗器械领域拥有25年以上的卖方覆盖经验。此前，他曾在ROTH Capital Partners、Oppenheimer、Thomas Weisel Partners、ABN AMRO和Leerink Swann & Co.等公司任职。Henry先生获得了无数奖项，包括华尔街日报“街头最佳”选股调查排名、福布斯/ZACS Investment Research药物类别“最佳分析师”排名以及Forbes.com/StarMine收益估计准确性排名。他的投资观点被《华尔街日报》和《纽约时报》引用，并在CNBC、CBS MarketWatch和彭博社频繁露面。Henry先生就读于罗德岛大学，并以优异的成绩获得了康奈尔大学的工商管理硕士学位。
- Scott R Henry has served on Nexgel, Inc.'s Board since January 16, 2023. Mr. Henry, CFA, is a Managing Director, Senior Research Analyst at Alliance Global Partners with 25+ years of sell side coverage in the pharmaceutical, biotechnology and medical device sectors. He has previously held positions with firms including ROTH Capital Partners, Oppenheimer, Thomas Weisel Partners, ABN AMRO and Leerink Swann & Co. Mr. Henry has received numerous awards, including rankings in the Wall Street Journal "Best on the Street" stock picking survey, Forbes/Zacks Investment Research "Best Analysts" for the drugs category and Forbes.com/StarMine rankings for earnings estimate accuracy. His investment views have been cited in the Wall Street Journal and the New York Times, and he has made frequent appearances on CNBC, CBS MarketWatch and Bloomberg. Mr. Henry attended the University of Rhode Island and received an M.B.A. with distinction from Cornell University.
- Brian J. Kieser
-
Brian J. Kieser是Fountainhead Lifesciences（f/k/a Fountainhead Biomedical Holdings）（“Fountainhead”）的创始人兼首席执行官，该公司是一家位于圣安东尼奥的风险投资平台，旨在创造、扩展下一代医疗技术并将其商业化。通过Fountainhead，Kieser先生组建了一个垂直整合的生态系统，由专注于骨科医疗设备、再生生物制剂和先进生物医学制造的公司组成，其中包括NVision Biomedical Technologies、Sequence LifeScience，Inc.（“Sequence”）和Lockhill Advanced Manufacturing Technologies。Kieser先生还担任Sequence的首席执行官。在创立Fountainhead之前，Kieser先生在批发分销、军政府承包和医疗保健等行业担任过多个财务和会计领导职务。Kieser先生拥有14项已发布的专利，涵盖用于独特识别植入医疗设备的结构编码技术和方法。Kieser先生在得克萨斯大学埃尔帕索分校获得会计学学士学位，是一名获得德克萨斯州执业许可的注册会计师。
Brian J. Kieser is the Founder and Chief Executive Officer of Fountainhead Lifesciences (f/k/a Fountainhead Biomedical Holdings) ("Fountainhead"), a San Antonio based venture platform designed to create, scale, and commercialize next generation medical technologies. Through Fountainhead, Mr. Kieser has assembled a vertically integrated ecosystem of companies focused on orthopedic medical devices, regenerative biologics, and advanced biomedical manufacturing, including Nvision Biomedical Technologies, Sequence LifeScience, Inc. ("Sequence"), and Lockhill Advanced Manufacturing Technologies. Mr. Kieser also serves as Chief Executive Officer of Sequence. Prior to founding Fountainhead, Mr. Kieser held several financial and accounting leadership roles in industries including wholesale distribution, military government contracting, and healthcare. Mr. Kieser holds 14 issued patents covering structural encoding technologies and methods used to uniquely identify implanted medical devices. Mr. Kieser earned his BBA in Accounting from the University of Texas at El Paso and is a Certified Public Accountant licensed to practice in Texas. - Brian J. Kieser是Fountainhead Lifesciences（f/k/a Fountainhead Biomedical Holdings）（“Fountainhead”）的创始人兼首席执行官，该公司是一家位于圣安东尼奥的风险投资平台，旨在创造、扩展下一代医疗技术并将其商业化。通过Fountainhead，Kieser先生组建了一个垂直整合的生态系统，由专注于骨科医疗设备、再生生物制剂和先进生物医学制造的公司组成，其中包括NVision Biomedical Technologies、Sequence LifeScience，Inc.（“Sequence”）和Lockhill Advanced Manufacturing Technologies。Kieser先生还担任Sequence的首席执行官。在创立Fountainhead之前，Kieser先生在批发分销、军政府承包和医疗保健等行业担任过多个财务和会计领导职务。Kieser先生拥有14项已发布的专利，涵盖用于独特识别植入医疗设备的结构编码技术和方法。Kieser先生在得克萨斯大学埃尔帕索分校获得会计学学士学位，是一名获得德克萨斯州执业许可的注册会计师。
- Brian J. Kieser is the Founder and Chief Executive Officer of Fountainhead Lifesciences (f/k/a Fountainhead Biomedical Holdings) ("Fountainhead"), a San Antonio based venture platform designed to create, scale, and commercialize next generation medical technologies. Through Fountainhead, Mr. Kieser has assembled a vertically integrated ecosystem of companies focused on orthopedic medical devices, regenerative biologics, and advanced biomedical manufacturing, including Nvision Biomedical Technologies, Sequence LifeScience, Inc. ("Sequence"), and Lockhill Advanced Manufacturing Technologies. Mr. Kieser also serves as Chief Executive Officer of Sequence. Prior to founding Fountainhead, Mr. Kieser held several financial and accounting leadership roles in industries including wholesale distribution, military government contracting, and healthcare. Mr. Kieser holds 14 issued patents covering structural encoding technologies and methods used to uniquely identify implanted medical devices. Mr. Kieser earned his BBA in Accounting from the University of Texas at El Paso and is a Certified Public Accountant licensed to practice in Texas.
- Kevin M. Harris
-
Kevin M. Harris自2026年5月6日起在NexGel, Inc.的董事会任职。Harris先生是Fountainhead的首席运营官，该公司是Sequence、NVISION Biomedical Technologies，Inc.和Cadaver Lab SA，LLC的母公司。他还担任Sequence的首席运营官。哈里斯先生在资产管理、资本市场和私营企业领导层拥有超过25年的经验，曾为超高净值家族和复杂组织监管超过20亿美元的资产。在加入Fountainhead之前，Harris先生曾担任O‘Reilly Development Company，LLC的合伙人兼首席投资官，在那里他领导了O’Reilly家族办公室的投资战略，并监督了价值超过5亿美元的多元化商业房地产投资组合的资产管理和资本结构工作。此前，哈里斯曾担任德州伙伴银行财富管理集团总裁兼首席投资官。哈里斯先生还是美国50家最大的独立注册投资咨询公司之一的联合创始人。在其职业生涯的早期，他曾在Frost Bank担任财富管理部门的首席投资官近十年。Harris先生是一名特许金融分析师，在得克萨斯大学圣安东尼奥分校获得会计学学士学位。Harris先生为董事会带来了在资本市场、资产管理和企业领导方面的丰富经验，这使他成为公司董事的合格人选。
Kevin M. Harris has served on Nexgel, Inc.'s Board since May 6, 2026. Mr. Harris is the Chief Operating Officer of Fountainhead, the parent company of Sequence, NVISION Biomedical Technologies, Inc., and Cadaver Lab SA, LLC. He also serves as the Chief Operating Officer of Sequence. Prior to joining Fountainhead, Mr. Harris served as Partner and Chief Investment Officer of O'Reilly Development Company, LLC, where he led investment strategy for the O'Reilly Family Office and oversaw asset management and capital structuring efforts for a diversified commercial real estate portfolio valued at more than $500 million. Earlier, Mr. Harris was President and Chief Investment Officer of Texas Partners Bank's Wealth Management Group. Mr. Harris was also a co founder of one of the 50 largest independent Registered Investment Advisory firms in the United States. Earlier in his career, he spent nearly a decade as Chief Investment Officer of the Wealth Management Division at Frost Bank. Mr. Harris is a Chartered Financial Analyst and earned a bachelor's degree in accounting from The University of Texas at San Antonio. - Kevin M. Harris自2026年5月6日起在NexGel, Inc.的董事会任职。Harris先生是Fountainhead的首席运营官，该公司是Sequence、NVISION Biomedical Technologies，Inc.和Cadaver Lab SA，LLC的母公司。他还担任Sequence的首席运营官。哈里斯先生在资产管理、资本市场和私营企业领导层拥有超过25年的经验，曾为超高净值家族和复杂组织监管超过20亿美元的资产。在加入Fountainhead之前，Harris先生曾担任O‘Reilly Development Company，LLC的合伙人兼首席投资官，在那里他领导了O’Reilly家族办公室的投资战略，并监督了价值超过5亿美元的多元化商业房地产投资组合的资产管理和资本结构工作。此前，哈里斯曾担任德州伙伴银行财富管理集团总裁兼首席投资官。哈里斯先生还是美国50家最大的独立注册投资咨询公司之一的联合创始人。在其职业生涯的早期，他曾在Frost Bank担任财富管理部门的首席投资官近十年。Harris先生是一名特许金融分析师，在得克萨斯大学圣安东尼奥分校获得会计学学士学位。Harris先生为董事会带来了在资本市场、资产管理和企业领导方面的丰富经验，这使他成为公司董事的合格人选。
- Kevin M. Harris has served on Nexgel, Inc.'s Board since May 6, 2026. Mr. Harris is the Chief Operating Officer of Fountainhead, the parent company of Sequence, NVISION Biomedical Technologies, Inc., and Cadaver Lab SA, LLC. He also serves as the Chief Operating Officer of Sequence. Prior to joining Fountainhead, Mr. Harris served as Partner and Chief Investment Officer of O'Reilly Development Company, LLC, where he led investment strategy for the O'Reilly Family Office and oversaw asset management and capital structuring efforts for a diversified commercial real estate portfolio valued at more than $500 million. Earlier, Mr. Harris was President and Chief Investment Officer of Texas Partners Bank's Wealth Management Group. Mr. Harris was also a co founder of one of the 50 largest independent Registered Investment Advisory firms in the United States. Earlier in his career, he spent nearly a decade as Chief Investment Officer of the Wealth Management Division at Frost Bank. Mr. Harris is a Chartered Financial Analyst and earned a bachelor's degree in accounting from The University of Texas at San Antonio.
- Jerome B. Zeldis
-
Jerome B. Zeldis，2012年9月起担任本公司董事。他目前是Celgene Global Health的首席执行官，也是Celgene Corporation的首席医学官，这是一个上市的生物制药公司，他自1997年起任职于该公司。之前，他担任Celgene的临床研究与医学事务高级副总裁。此前，他曾担任Harvard Medical School的医学副教授、University of California, Davis的医学副教授、Cornell Medical School的临床医学副教授、Robert Wood Johnson Medical School的临床医学教授。他在Brown University获得了学士学位、硕士学位，在Yale University获得分子生物物理学与生物化学免疫化学的学术硕士、医学博士、学术博士学位。他从2011年6月起，担任Soligenix的董事，这是生物制药上市公司；从2012年5月起，担任Alliqua的董事，这是一个生物医学公司。
Jerome B. Zeldis has been a director since June 2011. In March 2023 Dr. Zeldis retired as Executive Vice President, Research and Development of Neximmune. He was the Chief Medical Officer and President of Clinical Research, Drug Safety and Regulatory of Sorrento Therapeutics, Inc. and Celularity, Inc. Previously, Dr. Zeldis was Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company. He was employed by Celgene from 1997 to 2016. From September 1994 to February 1997, Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He has been a board member of several biotechnology companies and is currently on the boards of Metastat, Inc., PTC Therapeutics Inc., BioSig Technologies, Inc., the Castleman's Disease Organization and Alliqua, Inc. He has previously served on the boards of the NJ Chapter of the Arthritis Foundation and PTC Therapeutics, Inc. Additionally, he has served as Assistant Professor of Medicine at the Harvard Medical School from July 1987 to September 1988, Associate Professor of Medicine at University of California, Davis from September 1988 to September 1994, Clinical Associate Professor of Medicine at Cornell Medical School from January 1995 to December 2003 and Professor of Clinical Medicine at the Robert Wood Johnson Medical School from July 1998 to June 2010. Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. - Jerome B. Zeldis，2012年9月起担任本公司董事。他目前是Celgene Global Health的首席执行官，也是Celgene Corporation的首席医学官，这是一个上市的生物制药公司，他自1997年起任职于该公司。之前，他担任Celgene的临床研究与医学事务高级副总裁。此前，他曾担任Harvard Medical School的医学副教授、University of California, Davis的医学副教授、Cornell Medical School的临床医学副教授、Robert Wood Johnson Medical School的临床医学教授。他在Brown University获得了学士学位、硕士学位，在Yale University获得分子生物物理学与生物化学免疫化学的学术硕士、医学博士、学术博士学位。他从2011年6月起，担任Soligenix的董事，这是生物制药上市公司；从2012年5月起，担任Alliqua的董事，这是一个生物医学公司。
- Jerome B. Zeldis has been a director since June 2011. In March 2023 Dr. Zeldis retired as Executive Vice President, Research and Development of Neximmune. He was the Chief Medical Officer and President of Clinical Research, Drug Safety and Regulatory of Sorrento Therapeutics, Inc. and Celularity, Inc. Previously, Dr. Zeldis was Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company. He was employed by Celgene from 1997 to 2016. From September 1994 to February 1997, Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He has been a board member of several biotechnology companies and is currently on the boards of Metastat, Inc., PTC Therapeutics Inc., BioSig Technologies, Inc., the Castleman's Disease Organization and Alliqua, Inc. He has previously served on the boards of the NJ Chapter of the Arthritis Foundation and PTC Therapeutics, Inc. Additionally, he has served as Assistant Professor of Medicine at the Harvard Medical School from July 1987 to September 1988, Associate Professor of Medicine at University of California, Davis from September 1988 to September 1994, Clinical Associate Professor of Medicine at Cornell Medical School from January 1995 to December 2003 and Professor of Clinical Medicine at the Robert Wood Johnson Medical School from July 1998 to June 2010. Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School.
- Adam Levy
-
Adam Levy，自2019年9月10日起担任首席执行官兼总裁，并于2019年12月31日至2021年6月1日担任首席财务官。Levy先生也自2021年9月9日起担任董事会成员。Levy先生是与Cova Capital有关联的投资银行家，过去六年一直是资本市场专家。在此之前，他是Warlock Records Inc.及其相关公司自1985年成立以来的总裁兼首席执行官。在Warlock任职期间，作为滚动战略的一部分，他带领几家陷入财务困境的音乐公司成功扭亏为盈。他在消费品、市场营销、电视/广播广告和直接面向消费者的销售方面拥有专长。
Adam Levy has served as Nexgel, Inc.'s Chief Executive Officer and President since September 10, 2019 and was Nexgel, Inc.'s Chief Financial Officer from December 31, 2019 until June 1, 2021. Mr. Levy has also served on Nexgel, Inc.'s Board since September 9, 2021. Mr. Levy was an investment banker associated with Cova Capital for six years prior to joining NexGel and has significant capital markets experience. Prior to that, he was the president and CEO of Warlock Records Inc. and its related companies from its inception in 1985. While at Warlock, he led the successful turn around of several financially distressed music companies as part of a roll up strategy. Mr. Levy has expertise in consumer products, marketing, television/radio advertising and direct to consumer sales. - Adam Levy，自2019年9月10日起担任首席执行官兼总裁，并于2019年12月31日至2021年6月1日担任首席财务官。Levy先生也自2021年9月9日起担任董事会成员。Levy先生是与Cova Capital有关联的投资银行家，过去六年一直是资本市场专家。在此之前，他是Warlock Records Inc.及其相关公司自1985年成立以来的总裁兼首席执行官。在Warlock任职期间，作为滚动战略的一部分，他带领几家陷入财务困境的音乐公司成功扭亏为盈。他在消费品、市场营销、电视/广播广告和直接面向消费者的销售方面拥有专长。
- Adam Levy has served as Nexgel, Inc.'s Chief Executive Officer and President since September 10, 2019 and was Nexgel, Inc.'s Chief Financial Officer from December 31, 2019 until June 1, 2021. Mr. Levy has also served on Nexgel, Inc.'s Board since September 9, 2021. Mr. Levy was an investment banker associated with Cova Capital for six years prior to joining NexGel and has significant capital markets experience. Prior to that, he was the president and CEO of Warlock Records Inc. and its related companies from its inception in 1985. While at Warlock, he led the successful turn around of several financially distressed music companies as part of a roll up strategy. Mr. Levy has expertise in consumer products, marketing, television/radio advertising and direct to consumer sales.
高管简历
中英对照 | 中文 | 英文- Ian Blackman
Ian Blackman自2026年4月27日起担任NexGel, Inc.的首席财务官。布莱克曼先生是一名注册会计师，在私募股权支持和公开交易组织中拥有超过30年的全球金融领导经验。从2018年2月到2025年9月，布莱克曼先生担任McIntosh Group Inc.（及其继任者，Bose Luxury）的首席财务官，该公司是一家私募股权支持的豪华消费电子产品公司。从2017年4月到2018年1月，布莱克曼先生在Diptyque和Byredo这两个私募股权支持的奢侈生活方式品牌担任北美地区首席财务官。2015年5月至2017年3月，布莱克曼先生担任国际奢侈美妆品牌Trish McEvoy Ltd.的首席财务官。2011年9月至2015年4月，Blackman先生在JOC Group Inc.及其附属公司Breakbulk Inc.（一家国际数据服务集团的北美业务）担任首席财务官。从1995年到2011年9月，布莱克曼先生在环球音乐集团担任越来越重要的职务。布莱克曼先生的职业生涯始于Goldstein Golub Kessler and Company，1989年至1995年担任审计经理。布莱克曼先生拥有伦敦经济学院经济学理学（荣誉）学士学位。
Ian Blackman has served as Nexgel, Inc.'s Chief Financial Officer since April 27, 2026. Mr. Blackman is a Certified Public Accountant with over 30 years of global financial leadership experience across private equity backed and publicly traded organizations. From February 2018 until September 2025, Mr. Blackman served as Chief Financial Officer of McIntosh Group Inc. (and its successor, Bose Luxury), a private equity backed luxury consumer electronics company. From April 2017 to January 2018, Mr. Blackman served as Chief Financial Officer, North America, for Diptyque and Byredo, two private equity backed luxury lifestyle brands. From May 2015 to March 2017, Mr. Blackman served as Chief Financial Officer of Trish McEvoy Ltd., an international luxury beauty brand. From September 2011 to April 2015, Mr. Blackman served as Chief Financial Officer of JOC Group Inc. and its affiliate Breakbulk Inc., the North American businesses of an international data services group. From 1995 to September 2011, Mr. Blackman served in roles of increasing responsibility at Universal Music Group. Mr. Blackman began his career at Goldstein Golub Kessler and Company, where he served as an Audit Manager from 1989 to 1995. Mr. Blackman holds a Bachelor of Science (Honours) in Economics from the London School of Economics.- Ian Blackman自2026年4月27日起担任NexGel, Inc.的首席财务官。布莱克曼先生是一名注册会计师，在私募股权支持和公开交易组织中拥有超过30年的全球金融领导经验。从2018年2月到2025年9月，布莱克曼先生担任McIntosh Group Inc.（及其继任者，Bose Luxury）的首席财务官，该公司是一家私募股权支持的豪华消费电子产品公司。从2017年4月到2018年1月，布莱克曼先生在Diptyque和Byredo这两个私募股权支持的奢侈生活方式品牌担任北美地区首席财务官。2015年5月至2017年3月，布莱克曼先生担任国际奢侈美妆品牌Trish McEvoy Ltd.的首席财务官。2011年9月至2015年4月，Blackman先生在JOC Group Inc.及其附属公司Breakbulk Inc.（一家国际数据服务集团的北美业务）担任首席财务官。从1995年到2011年9月，布莱克曼先生在环球音乐集团担任越来越重要的职务。布莱克曼先生的职业生涯始于Goldstein Golub Kessler and Company，1989年至1995年担任审计经理。布莱克曼先生拥有伦敦经济学院经济学理学（荣誉）学士学位。
- Ian Blackman has served as Nexgel, Inc.'s Chief Financial Officer since April 27, 2026. Mr. Blackman is a Certified Public Accountant with over 30 years of global financial leadership experience across private equity backed and publicly traded organizations. From February 2018 until September 2025, Mr. Blackman served as Chief Financial Officer of McIntosh Group Inc. (and its successor, Bose Luxury), a private equity backed luxury consumer electronics company. From April 2017 to January 2018, Mr. Blackman served as Chief Financial Officer, North America, for Diptyque and Byredo, two private equity backed luxury lifestyle brands. From May 2015 to March 2017, Mr. Blackman served as Chief Financial Officer of Trish McEvoy Ltd., an international luxury beauty brand. From September 2011 to April 2015, Mr. Blackman served as Chief Financial Officer of JOC Group Inc. and its affiliate Breakbulk Inc., the North American businesses of an international data services group. From 1995 to September 2011, Mr. Blackman served in roles of increasing responsibility at Universal Music Group. Mr. Blackman began his career at Goldstein Golub Kessler and Company, where he served as an Audit Manager from 1989 to 1995. Mr. Blackman holds a Bachelor of Science (Honours) in Economics from the London School of Economics.
- Adam Levy
Adam Levy，自2019年9月10日起担任首席执行官兼总裁，并于2019年12月31日至2021年6月1日担任首席财务官。Levy先生也自2021年9月9日起担任董事会成员。Levy先生是与Cova Capital有关联的投资银行家，过去六年一直是资本市场专家。在此之前，他是Warlock Records Inc.及其相关公司自1985年成立以来的总裁兼首席执行官。在Warlock任职期间，作为滚动战略的一部分，他带领几家陷入财务困境的音乐公司成功扭亏为盈。他在消费品、市场营销、电视/广播广告和直接面向消费者的销售方面拥有专长。
Adam Levy has served as Nexgel, Inc.'s Chief Executive Officer and President since September 10, 2019 and was Nexgel, Inc.'s Chief Financial Officer from December 31, 2019 until June 1, 2021. Mr. Levy has also served on Nexgel, Inc.'s Board since September 9, 2021. Mr. Levy was an investment banker associated with Cova Capital for six years prior to joining NexGel and has significant capital markets experience. Prior to that, he was the president and CEO of Warlock Records Inc. and its related companies from its inception in 1985. While at Warlock, he led the successful turn around of several financially distressed music companies as part of a roll up strategy. Mr. Levy has expertise in consumer products, marketing, television/radio advertising and direct to consumer sales.- Adam Levy，自2019年9月10日起担任首席执行官兼总裁，并于2019年12月31日至2021年6月1日担任首席财务官。Levy先生也自2021年9月9日起担任董事会成员。Levy先生是与Cova Capital有关联的投资银行家，过去六年一直是资本市场专家。在此之前，他是Warlock Records Inc.及其相关公司自1985年成立以来的总裁兼首席执行官。在Warlock任职期间，作为滚动战略的一部分，他带领几家陷入财务困境的音乐公司成功扭亏为盈。他在消费品、市场营销、电视/广播广告和直接面向消费者的销售方面拥有专长。
- Adam Levy has served as Nexgel, Inc.'s Chief Executive Officer and President since September 10, 2019 and was Nexgel, Inc.'s Chief Financial Officer from December 31, 2019 until June 1, 2021. Mr. Levy has also served on Nexgel, Inc.'s Board since September 9, 2021. Mr. Levy was an investment banker associated with Cova Capital for six years prior to joining NexGel and has significant capital markets experience. Prior to that, he was the president and CEO of Warlock Records Inc. and its related companies from its inception in 1985. While at Warlock, he led the successful turn around of several financially distressed music companies as part of a roll up strategy. Mr. Levy has expertise in consumer products, marketing, television/radio advertising and direct to consumer sales.